The Serum Institute of India has defended the corona virus’s decision to increase the price of its vaccine covishield by one-and-a-half times what it was before. The company says that the initial price was based on advance funding and now it needs to invest more to increase production capacity, so it has to take a decision to increase the price. Regarding AstraZeneca’s most expensive vaccine in the world, Serum has said that such a comparison is wrong.
The price of vaccine being made in India is the highest here!
Corona Vaccine Price Issue: When Kejriwal asked Modi – why should the country be vacant at one rate?
The price of AstraZeneca’s Corona vaccine in India is double or even more than in most countries. Serum Institute faced criticism on social media after which it has to be clarified.
Now the price for the center is Rs 400 and for the states Rs 600 per dose
The Pune-based Serum Institute of India (SII) had earlier this week fixed the vaccine price at Rs 400 per dose for a new agreement with state governments and the central government and Rs 600 per dose for private hospitals. SII manufactures AstraZeneca’s Vaccine Covishield. It is currently supplying the vaccine at the rate of Rs 150 per dose to the central government.
Thief Returns Corona Vaccine: Thief Returned Vaccine By Speaking, Kumar Vishwas Shows Mirror To Leaders!
Covishield is still the cheapest vaccine available on the market today: Serum
SII said, “There has been an inaccurate comparison between the vaccine price in India and the global prices.” Kovishield is the cheapest Kovid-19 vaccine available on the market today. ‘ The company said the initial price was ‘low worldwide, as it was based on advance funding from countries that included the risk of vaccine manufacture.’ “The initial price of Kovishield was the lowest for all government immunization programs, including India,” the statement said.
Price of Rs 600 is not high: Serum
The company further said, ‘The current situation is completely different, the virus is constantly changing, while the public remains at risk. Identifying the uncertainty, we have to ensure stability, because we have to invest in capacity expansion to fight the epidemic and save the lives of people. ‘
SII said a small portion of the vaccine will be sold to private hospitals at a rate of Rs 600 per dose and that price is still lower than many other medical treatments.
(Input from language also)